Medical Director Articles

The term "article" is used to describe any bulletin article, web site article, educational handout or any other non-LCD document intended for public release that contains coverage/coding statements or medical review related billing or claims considerations.

Articles address local coverage, coding or medical review related billing and claims considerations, and may include any newly developed educational materials, coding instructions or clarification of existing medical review related billing or claims policy.

The article listing will continue to expand as additions are made.

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )
Articles Source Posted
Billing and Coding: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer (A58724) - R4 - Effective November 28, 2024 dic 02, 2024
Town Hall Meeting - December 10, 2024 nov 21, 2024
Billing and Coding: Lab: Flow Cytometry (A57690) - R11 - Effective October 1, 2024 nov 15, 2024
Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers Final LCD - Effective February 12, 2025 nov 14, 2024
Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers (A58997) - R8 - Effective July 11, 2024 nov 14, 2024
MolDX: Blood Product Molecular Antigen Typing (L38333) - R5 - Effective November 7, 2024 nov 07, 2024
Billing and Coding: MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) (A57424) - R4 - Effective November 7, 2024 nov 07, 2024
Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT )/Coronary Plaque Analysis (AI-CPA) Final LCD - Effective December 8, 2024 oct 31, 2024
Billing and Coding: Lab: Cystatin C Measurement (A57644) - R5 - Effective January 1, 2023 oct 24, 2024
Billing and Coding: MolDX: Pharmacogenomics Testing (A57385) - R14 - Effective August 1, 2024 oct 24, 2024
Billing and Coding: Computed Tomography Cerebral Perfusion Analysis (CTP) A58225 - R3 - Effective September 15, 2024 oct 17, 2024
Billing and Coding: Peripheral Nerve Stimulation (A55531) - R9 - Effective October 1, 2024 oct 17, 2024
Billing and Coding: Cervical Fusion (A59645) - R2 - Effective September 29, 2024 oct 10, 2024
2024 Q4 MolDX CPT/HCPCS Billing and Coding Article Updates - Effective October 1, 2024 oct 10, 2024
Billing and Coding: Respiratory Care (A57225) - R15 - Effective October 1, 2024 oct 10, 2024
2024 Q4 MolDX CPT/HCPCS Billing and Coding Article Updates - Effective October 1, 2024 oct 03, 2024
Billing and Coding: MolDX: ApoE Genotype (A55095) Retirement - Effective September 27, 2024 oct 03, 2024
Billing and Coding: Implantable Infusion Pumps for Chronic Pain (A55323) - R18 - Effective October 1, 2024 oct 03, 2024
2024 CPT/HCPCS Local Coverage Article (LCA) Updates oct 03, 2024
2024 ICD-10 Billing and Coding Article Updates - Effective October 1, 2024 oct 03, 2024
Proper Billing of Tuberculosis Test, CPT code 86481 sep 27, 2024
Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers (A58997) - R7 - Effective October 1, 2024 sep 26, 2024
MolDX: Percepta® Bronchial Genomic Classifier (L36891) Retirement - September 22, 2024 sep 26, 2024
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58456)- R8 - Effective September 26, 2024 sep 26, 2024
Micro-Invasive Glaucoma Surgery (MIGS) Final LCD - Effective November 17, 2024 sep 26, 2024
Benign Skin Lesion Removal (Excludes Actinic Keratosis, and Mohs) (A57162) - R4 - Effective October 1, 2015 sep 26, 2024
Self-Administered Drug Exclusion List (A53033) - R40 - Effective September 11, 2024 sep 26, 2024
Multijurisdictional Contractor Advisory Committee (CAC) Superficial Radiation Therapy (SRT) For The Treatment Of Nonmelanoma Skin Cancers (NMSC) - Bibliography sep 24, 2024
Billing and Coding: MolDX: BCR-ABL (A55600)- R5 - Effective September 19, 2024 sep 19, 2024
Urine Drug Testing - Published for Review and Comments sep 19, 2024
Noridian Molecular Diagnostic (MolDX) Updates from Provider Suggestion sep 17, 2024
Multi-Jurisdictional CAC Meeting Announcement - Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) - October 17, 2024, 2 - 4 p.m. CT sep 13, 2024
Multijurisdictional Contractor Advisory Committee (CAC) Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) - Agenda sep 13, 2024
Multijurisdictional Contractor Advisory Committee (CAC) Superficial Radiation Therapy (SRT) For The Treatment Of Nonmelanoma Skin Cancers (NMSC) - Key Questions sep 13, 2024
Billing and Coding: MolDX: Blood Product Molecular Antigen Typing (A57376) - R5 - Effective October 1, 2024 sep 12, 2024
Billing and Coding: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease (A57422) - R11 - Effective October 1, 2024 sep 12, 2024
Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer (A58681) - R7 - Effective October 1, 2024 sep 12, 2024
Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers (A58997) - R6 - Effective October 1, 2024 sep 12, 2024
Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (A57892) - R8 - Effective October 1, 2024 sep 12, 2024
Self-Administered Drug Exclusion List (A53033) - R39 - Effective June 4, 2015 sep 12, 2024
Billing and Coding: MolDX: bioTheranostics Cancer TYPE ID® Update (A54388) - R11 - Effective October 1, 2024 sep 05, 2024
Billing and Coding: MolDX: Repeat Germline Testing (A57332) - R13 - Effective September 5, 2024 sep 05, 2024
Intervertebral Disc Repair - Published for Review and Comments ago 29, 2024
Open Meeting Announcement Intervertebral Disc Repair - October 7, 2024 ago 29, 2024
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58726)- R20 - Effective October 1, 2024 ago 29, 2024
Open Meeting Announcement - Multiple MolDX Policies MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis and MolDX: Genetic Testing for Heritable Thoracic Aortic Disease - October 10, 2024 ago 29, 2024
Multiple MolDX Policies- MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis and MolDX: Genetic Testing for Heritable Thoracic Aortic Disease - Published for Review and Comments ago 29, 2024
MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis (L39469) - R1 - Effective August 22, 2024 ago 22, 2024
MolDX: Molecular Testing for Solid Organ Allograft Rejection ago 16, 2024
Noridian Molecular Diagnostic Service New Look ago 09, 2024